Sarepta Therapeutics, Inc.
Functionally-Modified Oligonucleotides And Subunits Thereof

Last updated:

Abstract:

Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3' and/or 5'-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Status:
Application
Type:

Utility

Filling date:

10 Nov 2021

Issue date:

28 Apr 2022